ClinConnect ClinConnect Logo
Search / Trial NCT06979466

Q Therapeutic System for Chronic Stroke Recovery

Launched by BURKE REHABILITATION HOSPITAL · May 13, 2025

Trial Information

Current as of August 19, 2025

Recruiting

Keywords

Brain Q Stroke Cerebrovascular Disorders Electromagnetic Stimulation

ClinConnect Summary

This clinical trial is testing a new treatment called the Q Therapeutic (BQ 3.0) System to help people who have had a stroke improve the movement and function of their affected arm and hand. The study is focused on individuals who had a stroke at least six months ago but no more than five years ago and still experience some difficulty using their upper limbs. The goal is to see if using this system through a combination of therapy sessions at the clinic and exercises done at home over three months can help improve arm function.

To join the study, participants need to be between 18 and 80 years old and have some ability to move their affected arm, as measured by specific tests. They must be able to sit comfortably for about 40 minutes and follow simple instructions. A caregiver or family member should be available to help during treatment sessions. People who have severe memory or movement problems, uncontrolled seizures, serious health issues, or who recently received other specific treatments for their arm may not be eligible. Participants can expect regular therapy sessions using the Q Therapeutic System, both in the clinic and at home, designed to support their recovery and improve arm use after stroke.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • FMA-UE score between 22-50 (inclusive) of impaired limb.
  • Difference between Screening and Baseline visit FMA-UE is 3 points or fewer.
  • Age 18 to 80 years of age (inclusive).
  • Stroke due to ischemia or to intracerebral hemorrhage.
  • \>6 months to 5 years from index stroke onset.
  • Box \& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit.
  • Able to sit with the investigational System for 40 consecutive minutes.
  • Can follow a 3-step command, such as "take the paper, fold it in half, and return it to me", or a non-verbal equivalent.
  • Willingness to participate in physical exercises during study intervention sessions.
  • Availability of a relative or other caregiver able to assist during study treatment sessions and visits.
  • If female, not pregnant or breastfeeding or planning pregnancy during the study period.
  • Informed consent signed by subject.
  • Exclusion Criteria:
  • Severe neglect impairment interfering with assessments or treatments.
  • Severe depression, defined as GDS Score \>10/15
  • The presence of MR-incompatible implanted devices or MR-incompatible retained objects; or the presence of life-sustaining MR-compatible devices (e.g. pacemaker or internal cardiac defibrillator).
  • Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or any epileptic seizure in the last 5 years
  • Botulinum toxin to the paretic arm: received in the prior 3 months OR expected before the 6-Month Visit
  • Severe UE spasticity, defined as presence of upper extremity contracture or modified Ashworth Scale score≥3 in either biceps or pectoralis
  • Pre-existing neurological condition (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or physical limitation that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
  • Significant visual disturbances, pre-existing or resulting from the index stroke, that cannot be corrected and that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
  • Unstable serious illness/condition (eg, active cancer, severe heart failure, active major psychiatric condition) or life expectancy of less than 12 months.
  • Alcohol abuse and/or illicit drug abuse in the past 6 months, which is likely to influence ability to fully participate in the trial.
  • Participation in another interventional trial that would conflict with the current study or clinical endpoint interference may occur.
  • Participation in an upper extremity rehabilitation program provided by a licensed provider in the 4 weeks prior to the Screening visit, or a or planned participation in such program at any time between the Screening Visit and the primary endpoint visit.
  • Employee of the Sponsor.
  • Prisoner.

About Burke Rehabilitation Hospital

Burke Rehabilitation Hospital is a leading healthcare institution specializing in rehabilitation services, dedicated to enhancing the quality of life for patients recovering from disabilities, injuries, and chronic conditions. Renowned for its comprehensive approach to patient care, Burke combines advanced medical expertise with innovative rehabilitation techniques to deliver personalized treatment plans. The hospital actively engages in clinical trials aimed at advancing rehabilitation practices and improving patient outcomes. With a commitment to research and excellence in care, Burke Rehabilitation Hospital plays a pivotal role in transforming rehabilitation methodologies and contributing to the broader medical community.

Locations

White Plains, New York, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported